Efficacy of Maternal Influenza Vaccination Against All-Cause Lower Respiratory Tract Infection Hospitalizations in Young Infants: Results From a Randomized Controlled Trial

Nunes, Marta C.; Cutland, Clare; Jones, Stephanie; Downs, Sarah; Weinberg, Adriana; Ortiz, Justin R.; Neuzil, Kathleen M.; Simões, Eric A F; Klugman, Keith P.; Madhi, Shabir А.

doi:10.1093/cid/cix497

Cited by 69 publications

(60 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pregnant women are considered by the WHO as the main high‐risk group during pandemics. Maternal immunization can reduce the risk of post‐natal infections in the infants . Currently, two studies among pregnant women are ongoing in Tunisia and Saudi Arabia.…”

Section: Discussion and Concluding Remarksmentioning

confidence: 99%

Influenza surveillance in Middle East, North, East and South Africa: Report of the 8th MENA Influenza Stakeholders Network

Abusrewil

Algeer²,

Aljifri

et al. 2019

Influenza Resp Viruses

View full text Add to dashboard Cite

The Middle‐East and Africa Influenza Surveillance Network ( MENA ‐ ISN ), established in 2014, includes 15 countries at present. Country representatives presented their influenza surveillance programmes, vaccine coverage and influenza control actions achieved, and provided a list of country surveillance/control objectives for the upcoming 3 years. This report details the current situation of influenza surveillance and action plans to move forward in MENA ‐ ISN countries. Data were presented at the 8th MENA ‐ ISN meeting, organized by the Mérieux Foundation that was held on 10‐11 April 2018 in Cairo, Egypt. The meeting included MENA ‐ ISN representatives from 12 countries (Algeria, Egypt, Jordan, Kenya, Lebanon, Libya, Morocco, Pakistan, Saudi Arabia, South Africa, Tunisia and United Arab Emirates) and experts from the Canadian Centre for Vaccinology, and the World Health Organization. Meeting participants concluded that influenza remains a significant threat especially in high‐risk groups (children under‐5, elderly, pregnant women and immunosuppressed individuals) in the MENA ‐ ISN region. Additional funding and planning are required by member countries to contain this threat. Future meetings will need to focus on creative and innovative ways to inform policy and initiatives for vaccination, surveillance and management of influenza‐related morbidity and mortality especially among the most vulnerable groups of the population.

show abstract

Section: Discussion and Concluding Remarksmentioning

confidence: 99%

Influenza surveillance in Middle East, North, East and South Africa: Report of the 8th MENA Influenza Stakeholders Network

Abusrewil

Algeer²,

Aljifri

et al. 2019

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…The need to protect neonates and infants in the first 6 months of life from influenza is so important that many health authorities have recommended influenza vaccinations of pregnant women [49][50][51]. Studies have shown that vaccination during pregnancy is effective in reducing influenza cases for at least one influenza season [52,53].…”

Section: Influenza Vaccinationmentioning

confidence: 99%

Vaccination against Paediatric Respiratory Pathogens

et al. 2019

View full text Add to dashboard Cite

Acute respiratory infections (ARIs) are extremely common in children, especially those under 5 years old. They can lead to complications, super-infection, respiratory failure, and even compromised respiratory function in adulthood. For some of the responsible pathogens, vaccines are available. This review reports current issues about vaccines against the main respiratory pathogens to highlight the available strategies to reduce the burden of paediatric respiratory disease. The optimal use of influenza, pneumococcal, pertussis and measles vaccines is required in order to reduce ARI burden. Vaccination coverage rates must be improved to achieve the full benefits of these vaccines. Recently, advances in the knowledge of respiratory syncytial virus structural biology and immunology as well as the development of new techniques to generate vaccine candidates have increased the number of promising vaccines even against this harmful pathogen.

show abstract

“…Studies varied by study design, vaccine type (inactivated influenza vaccine, IIV3; live attenuated influenza vaccine, LAIV) and study population (Table 1). 16 were from South Africa, [11][12][13][14][16][17][18][19]23,25,[27][28][29][30][31][32] two each from Gabon 21,22 and Kenya, 20,26 and one study each from Mali 15,33 Senegal 24 and The Gambia. 33 The following study populations were identified: pregnant women (6 studies), children (6), elderly (3), HIV-Positive adults (1), healthcare workers (1) and all age groups (6).…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

“…One RCT from South Africa 11 and one from Mali 15 evaluated influenza vaccination in pregnant women, with three studies reporting secondary analyses from the South Africa RCT [12][13][14] and one study reporting a secondary analysis from both RCTs (Supplementary table 1). 31 A single centre, randomised, double-blind placebo-controlled trial including HIV-uninfected and HIV-infected pregnant women (60% on HAART at enrolment, median CD4 count 393•5 cells/mm 3 ) was conducted in South Africa.…”

Section: Influenza Vaccination In Pregnant Womenmentioning

confidence: 99%

The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review

Lindsey

Armitage

Kampmann

et al. 2019

The Lancet Infectious Diseases

View full text Add to dashboard Cite

The burden of influenza in Africa is significant and under-appreciated. While surveillance has increased, our understanding of seasonal influenza vaccine performance remains limited. We conducted a systematic review, using PRISMA guidelines (PROSPERO CRD42017058107), on the efficacy, effectiveness and immunogenicity of influenza vaccines in populations within Africa with the aim of identifying key data gaps to help direct future research. We searched Embase, Medline, Global Health and Web of Science for published studies from database inception to May 9 th , 2018. Unpublished studies were identified by searching ClinicalTrials.gov and the Pan-African Clinical Trial Registry and by contacting experts within the field. Human studies which reported influenza vaccine immunogenicity, effectiveness and efficacy were included. The quality of each study was assessed using the GRADE framework. 1746 articles were assessed and 23 articles included: six maternal immunisation, 6 child immunisation, three elderly immunisation and 8 other articles. Only three studies were of high quality and many studies were under-powered. All studies came from only six African countries (16 from South Africa), highlighting the need for data from a broader range of African populations. The majority of studies focused on effectiveness or efficacy against laboratory confirmed influenza with limited data on severe outcomes. Several factors known to interfere with influenza immunization, such as malaria, HIV and malnutrition were under-represented in this review and require further study. Significant gaps exist in our understanding of influenza vaccine performance across all WHO high risk groups in Africa.

show abstract

Efficacy of Maternal Influenza Vaccination Against All-Cause Lower Respiratory Tract Infection Hospitalizations in Young Infants: Results From a Randomized Controlled Trial

Cited by 69 publications

References 33 publications

Influenza surveillance in Middle East, North, East and South Africa: Report of the 8th MENA Influenza Stakeholders Network

Influenza surveillance in Middle East, North, East and South Africa: Report of the 8th MENA Influenza Stakeholders Network

Vaccination against Paediatric Respiratory Pathogens

The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review

Contact Info

Product

Resources

About